Bayer receives US approval for modern hemophilia A treatment Jivi ® with a step-wise prophylaxis dosing regimen (for specialized target groups only)

Jivi’s extended half-life allows for twice-weekly initial dosing / May be adjusted to every five days and further individually adjusted to less or more frequent dosing
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news